Immuuntherapie ontwikkeling bladder cancer head & neck cancer Lung cancer melanoma ovarian cancer
Conditions
Interventions
Sponsors
Antoni van Leeuwenhoek Ziekenhuis
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: a. Age >=18 years b. Written informed consent c. Histologically proven NSCLC, bladder, ovarian, melanoma, or head & neck cancer d. Performance score WHO 0 or 1 at time of study entry e. An indication for a routine diagnostic investigation or for therapeutic or palliative surgery during which a tumor biopsy can be taken or the presence of metastatic lesion(s) of which a biopsy can safely be obtained I. Patients with safely accessible metastases according to an interventional-radiologist* II. Patients not known to have bleeding disorders (such as hemophilia) or bleeding complications from biopsies, dental procedures or surgeries* f. Expected biopsy size of at least 5 core biopsies or 100 mm3 ;*These criteria are only applicable if the patient will have a biopsy solely for the purpose of this study.
Exclusion criteria
Exclusion criteria: a. Anemia (Hb 10 mg) or any other form of immunosuppressive drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter/endpoint per patient will be the number and frequency of T-cell responses that can be generated against tumor neoantigens predicted from the autologous tumor mutanome of the patient. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary study parameter/endpoint will be the frequency, phenotype, and functionality of the induced T-cells as characterized by functional assays and flow cytometry. | — |
Countries
The Netherlands
Outcome results
None listed